Deadline Approaching: Lantheus Holdings, Inc. (NASDAQ: LNTH) Investors Who Incurred Losses Have Until November 10, 2025, to Contact The Law Offices of Frank R. Cruz Regarding Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz reminds investors that the deadline to seek appointment as lead plaintiff in the securities fraud class action lawsuit filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) is rapidly approaching. Investors who purchased or otherwise acquired Lantheus securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”) have until November 10, 2025, to participate in this important litigation.
the Case
The class action lawsuit has been filed in the United States District Court and seeks to recover damages for investors under federal securities laws. The complaint alleges that throughout the Class Period, Lantheus Holdings, Inc. and certain of its senior executives made materially false and/or misleading statements and failed to disclose critical information regarding the Company’s business, operations, and future prospects—particularly relating to its key oncology product, Pylarify.
Lantheus, a leading diagnostic and therapeutic imaging company, is known for its radiopharmaceutical products used in the detection and treatment of diseases such as prostate cancer. Among its portfolio, Pylarify, a PSMA-targeted PET imaging agent, has been a significant driver of the Company’s growth and revenue in recent years. Investors relied heavily on the Company’s projections for Pylarify when assessing Lantheus’s overall performance and valuation.
However, as alleged in the lawsuit, during the Class Period, Lantheus misrepresented the true demand trends, competitive landscape, and pricing dynamics associated with Pylarify. When the truth emerged, the Company’s stock price plummeted, causing substantial losses for investors.
What Happened
The troubles began to surface Approaching when Lantheus released its first-quarter 2025 financial results on May 7, 2025. While analysts and investors had expected continued robust growth in Pylarify sales, the Company instead reported weaker-than-anticipated financial results and disclosed an unexpected decline in Pylarify’s year-over-year performance.
According to the Company, the disappointing results stemmed from a “temporal competitive disruption” in the marketplace. This phrase, which puzzled many investors and analysts, referred to increased competition that temporarily hindered Pylarify’s market position. At the same time, management revised its full-year 2025 financial guidance downward, signaling potential ongoing challenges.
The market reacted swiftly. On the day of the announcement, Lantheus’s stock price dropped sharply by $24.35 per share—approximately 23.2%—closing at $80.49 on May 7, 2025. This significant decline represented a major setback for investors, many of whom had purchased shares at higher valuations based on optimistic growth projections.
Unfortunately, the May Approaching earnings disappointment was only the beginning.
Continued Decline and Investor Losses
On August 6, 2025, Lantheus released its second-quarter 2025 financial results, and the news once again fell far short of expectations. The Company not only missed Wall Street’s consensus estimates but also disclosed that growth expectations for Pylarify had been further reduced due to what it described as “ongoing competition impacting pricing dynamics.”
This admission confirmed that the Deadline Approaching earlier issues had not been temporary as initially suggested. Instead, Pylarify’s performance was being severely pressured by competitive products, which were affecting both sales volumes and pricing power.
Investors were quick to react to this second wave of bad news. The Company’s share price fell another $20.76 per share—or 28.6%—closing at $51.87 on August 6, 2025. This compounded the earlier losses from May and erased hundreds of millions of dollars in shareholder value.
These successive declines demonstrated that the Company’s prior assurances and forward-looking statements about its competitive positioning and growth trajectory had been materially misleading.
The Core Allegations
According to the complaint, Lantheus and certain senior executives violated the Securities Exchange Act of 1934 by issuing false and/or misleading statements and failing to disclose material adverse facts about the Company’s business operations and prospects.
Specifically, the lawsuit alleges that during the Class Period:
- Lantheus overstated the demand and growth prospects for Pylarify, its leading Radiopharmaceutical Oncology product.
- The Company failed to disclose the extent and impact of competitive pressures that were eroding Pylarify’s market share.
- Lantheus misled investors by attributing sales declines to temporary market disruptions, rather than structural challenges within its product segment.
- As a result of these omissions and misrepresentations, Lantheus’s statements about its financial condition, operations, and future prospects were materially false and misleading, leading investors to purchase shares at artificially inflated prices.
When the true facts were revealed through the May and August 2025 financial disclosures, the stock price fell dramatically, causing investors to suffer substantial losses.
What Investors Can Do
If you purchased Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025, and August 5, 2025, and suffered financial losses, you may be eligible to serve as lead plaintiff in the class action lawsuit.
The lead plaintiff acts as a representative party for other class members in directing the litigation. Your ability to share in any potential recovery does not require you to serve as lead plaintiff; you can remain an absent class member and still benefit from any eventual settlement or judgment.
Investors who wish to be considered for lead plaintiff must file a motion with the Court no later than November 10, 2025.
Why Legal Action Matter
Securities class actions like this one play a critical role in maintaining market integrity. When companies fail to provide investors with truthful and transparent information, they distort the marketplace and erode investor confidence. The goal of such litigation is to recover losses for shareholders and hold corporate executives accountable for their misrepresentations.
By pursuing legal remedies, investors also help deter future misconduct in the financial markets. The case against Lantheus will examine whether Company executives acted negligently or knowingly misled shareholders about Pylarify’s competitive standing and the Company’s revenue outlook.
The Road Ahead
As the case proceeds, the Court will determine whether the defendants’ alleged misrepresentations violated federal securities laws and whether investors are entitled to recover damages. Legal experts expect that additional evidence—such as internal communications, analyst reports, and witness testimony—will shed light on how much the Company’s leadership knew about the emerging competitive threats when making their public statements.
In the meantime, affected investors are urged to act quickly. The November 10, 2025 deadline is approaching, and those who wish to participate in the litigation or serve as lead plaintiff must contact counsel before that date to preserve their rights.
About Lantheus Holdings, Inc.
Headquartered in Bedford, Massachusetts, Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents used in medical imaging and targeted therapy. Its portfolio includes several important products for detecting and treating cardiovascular diseases and cancer.
The Company’s Pylarify (piflufolastat F 18) is a PET imaging agent designed to identify prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer. Pylarify has been a critical revenue driver since its FDA approval, contributing significantly to Lantheus’s market valuation.
However, as the lawsuit underscores, competitive pressures within the radiopharmaceutical oncology space have intensified, raising questions about the sustainability of Pylarify’s market dominance and Lantheus’s growth trajectory.
source link: https://www.businesswire.com
